[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharmala Biotech Holdings Inc. (MDMA.CN)

Pharmala Biotech Holdings Inc. (MDMA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 17,475
  • Shares Outstanding, K 109,217
  • Annual Sales, $ 605 K
  • Annual Income, $ -2,175 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.95
  • Price/Sales 18.95
  • Price/Cash Flow N/A
  • Price/Book 8.10

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1350 +14.81%
on 07/16/26
0.1750 -11.43%
on 07/21/26
+0.0150 (+10.71%)
since 06/26/26
3-Month
0.1300 +19.23%
on 06/24/26
0.1950 -20.51%
on 05/20/26
-0.0100 (-6.06%)
since 04/27/26
52-Week
0.0850 +82.35%
on 04/09/26
0.1950 -20.51%
on 05/20/26
+0.0500 (+47.62%)
since 07/25/25

Most Recent Stories

More News
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.1113 (+1.37%)
JUNS : 0.1094 (-9.59%)
MDMA.CN : 0.1550 (-3.13%)
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing...

MDXXF : 0.1113 (+1.37%)
JUNS : 0.1094 (-9.59%)
MDMA.CN : 0.1550 (-3.13%)
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May...

JUNS : 0.1094 (-9.59%)
MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ( “PharmAla” or the “Company” ), a leader in the research, development, and manufacturing...

MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
Upcoming Meeting Dates - May 11, 2026

Toronto, Ontario -- (Newsfile Corp. - May 11, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through...

GRB.VN : 0.700 (+7.69%)
SHRX.VN : 0.910 (-9.00%)
CURA.TO : 12.66 (-2.31%)
STGO.TO : 1.24 (-0.40%)
IMC.VN : 0.025 (unch)
ULTH.CN : 0.4100 (unch)
RNCH.VN : 0.040 (unch)
AIC.CN : 0.4000 (unch)
BTC.CN : 0.1100 (unch)
ADYA.VN : 0.370 (unch)
FHR.VN : 0.075 (unch)
CVW.VN : 0.760 (unch)
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company focused on the research, development,...

MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development and manufacturing of MDMA...

MDXXF : 0.1113 (+1.37%)
MDMA.CN : 0.1550 (-3.13%)
Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine)....

MDXXF : 0.1113 (+1.37%)
VIT.AX : 0.028 (-6.67%)
MDMA.CN : 0.1550 (-3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active...

See More

Key Turning Points

3rd Resistance Point 0.1667
2nd Resistance Point 0.1633
1st Resistance Point 0.1617
Last Price 0.1550
1st Support Level 0.1567
2nd Support Level 0.1533
3rd Support Level 0.1517

See More

52-Week High 0.1950
Last Price 0.1550
Fibonacci 61.8% 0.1530
Fibonacci 50% 0.1400
Fibonacci 38.2% 0.1270
52-Week Low 0.0850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.